Details of Disease

General Information of Disease (ID: DIS4Q1R7)

Disease Name Geographic atrophy
Disease Class 9B75: Macular degeneration
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DIS4Q1R7: Geographic atrophy
ICD Code
ICD-11
ICD-11: 9B75
Disease Identifiers
MESH ID
D057092
MedGen ID
323488
HPO ID
HP:0031609

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 1 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Avacincaptad pegol DM1Z3Z2 Approved NA [1]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
GT005 DMCA120 Phase 2 NA [2]
NGM621 DM84DP5 Phase 2 Antibody [3]
RG6299 DMVJL8W Phase 2 Antisense oligonucleotide [4]
RG6501 DM5EZWZ Phase 1 Cell therapy [4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217225
2 ClinicalTrials.gov (NCT04566445) HORIZON: A Phase II, Open-label, Outcomes-assessor Masked, Multicentre, Randomised, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration. U.S.National Institutes of Health.
3 ClinicalTrials.gov (NCT04465955) A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD). U.S.National Institutes of Health.
4 Clinical pipeline report, company report or official report of Roche